CHCarmen Dagmar Mariaca Hajducek

Carmen Dagmar Mariaca Hajducek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmen Dagmar Mariaca Hajducek has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance-Based Usability of Medication Adherence Technologies Among Older Adults With Diverse Capabilities: Quantitative Study

    by Bincy Baby, Ghada Elba, SooMin Park, Imra Hudani, Rishabh Sharma, Kirk Patterson, Annette McKinnon, Sara J T Guilcher, Feng Chang, Linda Lee, et al.

    Background: Medication adherence technologies (MATs) offer innovative solutions to support older adults in managing complex medication regimens, yet usability challenges can prevent their successful use. Older adults often face cognitive, physical, sensory, motivational, and environmental barriers, which can influence how they interact with these devices. Therefore, performance-based usability testing is essential for identifying usability issues. Objective: This study aimed to evaluate the performance-based usability and user experience of 13 MATs among older adults with diverse capabilities. Methods: A prospective mixed methods design was used, with 96 participants aged 60 years and older testing smart and electronic MATs using cognitive walkthroughs and predefined usability tasks without formal training to simulate first-use conditions. This manuscript focuses specifically on the performance-based usability metrics collected as part of the mixed methods study. Validated tools, including the Self-Medication Assessment Tool (SMAT), Daily Living Tasks Dependent on Vision (DLTV), Whisper Test, Self-Efficacy for Appropriate Medication Use Scale (SEAMS), and Martin and Park Environmental Demands (MPED) Questionnaire, were used to assess individual barriers. Poisson generalized estimating equations (GEE) was used to determine predictors of unassisted task success and error rates while accounting for repeated observations. Results: A total of 96 participants (mean age 75.1, SD 7.7, range 61‐95 y) were included, with 37.5% (36/96) male and 62.5% (60/96) female. Poisson GEE models identified significant predictors of unassisted task success rate, including cognitive score ( P <.001), physical score ( P <.001), vision score ( P <.001), motivational score ( P <.001), and lower environmental busyness ( P =.049). Female sex was associated with a 9% lower success rate ( P =.002). Predictors of total error rate included age ( P =.02), sex ( P ≤.001), physical score ( P ≤.001), vision score ( P =.004), DLTV vision score ( P =.01), MPED routine score (environmental; P =.05), and interaction between physical score and sex ( P =.004). Conclusions: Both device design and user characteristics strongly influence the usability of MATs. Performance-based evaluations provide actionable findings for user-centered design and selection, guiding manufacturers and health care providers toward developing and choosing accessible technologies that could improve medication adherence among older adults.

  • Open Access

    El derecho a ser científicas Colección de ensayos Volumen 1

    by María Elena Tejeda Yeomans, Dulce María Vargas Bracamontes, Julia Tagüeña Parga, Ana Júlia Silveira Mizher, Carmen Dagmar Mariaca Hajducek, Elizabeth Ivonne Rovere, Isabel Cordero Carrión, Maura Elizabeth Ramírez Quezada, Olga Olinca Galván de la Cruz, Sara Guillermina Centeno Leija, et al.

    ¿Qué se necesita para ser científica? ¿Qué obstáculos enfrentan las mujeres que desean dedicarse a la ciencia? ¿Cómo abrir caminos para que más niñas y jóvenes puedan lograrlo? Este libro reúne las voces de ocho científicas de México, Brasil, Argentina y España, quienes comparten, desde sus vivencias y reflexiones, cómo nació su interés por la ciencia, los desafíos que han enfrentado y los logros alcanzados a lo largo de sus trayectorias. Sus historias reflejan no sólo un profundo compromiso con el conocimiento, sino también su perseverancia frente a obstáculos estructurales que aún limitan el acceso de las mujeres al ámbito científico. En estas historias contadas por sus protagonistas, el ser científica de manera activa y con agencia, es el motor de cambio para gozar de la ciencia. A través de sus relatos, comprendemos que el derecho a ser científica no es sólo una cuestión de equidad y justicia: es clave para el avance de nuestras sociedades y el bienestar colectivo. Se trata de una invitación a imaginar nuevos futuros, a inspirarse en quienes ya están abriendo camino y a sumarse a la construcción del quehacer científico diverso e incluyente. El derecho a ser científicas. Colección de ensayos está pensado para ti, que quizás estás descubriendo lo que te apasiona, que te preguntas si también podrías formar parte de ese universo llamado ciencia. La respuesta no está escrita en una sola historia, sino en todas estas voces que, al reunirse, te invitan a encontrar la tuya. Porque el futuro también se construye con mujeres en la ciencia.

  • Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding

    by Santosh V. Suryavanshi, Shirley Wang, Dagmar M. Hajducek, Abdullah Hamadeh, Cindy H. T. Yeung, Patricia D. Maglalang, Shinya Ito, Julie Autmizguine, Daniel Gonzalez, Andrea N. Edginton

    Background and Objective Although breastfeeding ensures optimal infant development and maternal health, mothers taking medications may abandon breastfeeding because of uncertainties regarding toxicity to infants. Current methods in predicting infant risk to maternal medication exposure do not account for breastfeeding-related variability or in utero exposure via the umbilical cord (UC). Previously, our workflow integrated variability in infant anatomy and physiology, breast milk intake volume, and drug concentrations in breast milk using physiologically based pharmacokinetic (PBPK) modeling. The upper area under the curve ratio (UAR) was then calculated to assess infant risk from maternal drug. Herein, we enhanced this workflow by coupling pre- and postnatal exposures to predict the overall levetiracetam exposure in breastfeeding infants. Methods A published pediatric PBPK model of levetiracetam was used to simulate an infant population (n = 100). Daily infant doses were simulated using a weight-normalized milk intake model to calculate volumes ingested across age groups, alongside literature-derived or simulated milk concentrations across maternal doses to predict infant concentrations. Published UC concentrations were used to develop a cord-coupled neonatal model (CCM), which was integrated with the PBPK and milk intake models and evaluated by comparing observed and simulated infant blood concentrations using a 90% prediction interval (PI). Results UC concentration data from 14 mothers were used to develop the CCM. A total of 16 paired (known milk concentrations) and two unpaired (unknown milk concentrations) individual infant concentrations were identified for evaluating the model along with population values of 64 infants from two age groups (2–4 and 7–31 days). The CCM improved the predictions overall compared with the original workflow, largely due to improvements for the youngest age group evaluated. Overall, 83% (10 of 12) of the individual infant plasma concentrations were successfully captured within the 90% PI for the paired, quantifiable (i.e. above the limit of quantification) evaluation datasets. After administration of a maternal dose of levetiracetam 2000 mg, the calculated UAR ranged from 0.13 to 0.27 for the 95th percentile infants. Conclusions To our knowledge, this is the first report to combine prenatal levetiracetam exposures from the UC and postnatal exposures from breastfeeding to predict overall infant drug exposure. The results indicate that infant exposure in infants aged 0–7 days may approach therapeutic levels of levetiracetam in the highest-risk infants (i.e. 95th percentile), with a low likelihood of adverse effects based on published clinical studies. This integrated modeling approach provides a more holistic analysis of neonatal exposures. It can be applied in future studies to derive the UAR of drugs administered during breastfeeding to identify infants at risk of potential toxicity.


  • Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans

    by Min-Soo Kim, Dagmar M. Hajducek, James C. Gilbert, Alfonso Iorio, Bernd Jilma, Andrea N. Edginton

    Lack of Factor VIII (FVIII) concentrates is one of limiting factors for Hemophilia A prophylaxis in resource-limited countries. Rondaptivon pegol (BT200) i